Globus Medical, the US spine and neurosurgery specialist, has seen its share price come under pressure this year, which puts a sharper spotlight on whether today's valuation is properly grounded in the cash the business can generate. With fresh headlines around acquisitions and capital returns, the question is how much of its future cash flows are already baked into the current price.
- Over the past 3 years the stock has returned about 60.9%, which makes the link between that rise and the underlying cash flow profile crucial for anyone considering the current valuation.
- The purchase of Synaptive Medical and management's focus on Enabling Technologies, along with a larger share repurchase program, can influence expectations for future cash generation, margin mix, and how much free cash ultimately reaches shareholders.
- If you'd rather focus on earnings, this one's for you. See what Globus Medical's 16.9x P/E says about the price.
The issue now is whether Globus Medical's recent share price, after a weaker 12 month patch, is fully supported by the intrinsic value suggested by its cash flows under a Discounted Cash Flow (DCF) lens.
If you want a broader sense of how Globus Medical's valuation story compares to other opportunities, line it up against companies in 38 high quality undervalued stocks
Is Globus Medical Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) model here focuses on the cash that Globus Medical can return to shareholders over time. Latest twelve month free cash flow sits at about $770.2 million, and the projections used in the model assume that future free cash flow trends gently lower from that level before settling into relatively steady long term growth. That profile looks more like a mature cash generator than a high risk, high growth story.
On those assumptions, the DCF outcome puts Globus Medical's estimated intrinsic value substantially above the current share price of $71.05. The acquisition of Synaptive Medical, which expands Globus Medical's reach in cranial neurosurgery, fits with those cash flow expectations because it leans into higher value enabling technologies without the model banking on sharp free cash flow acceleration. For a reader weighing what the current market price implies, the key point is that the cash flow stream used in the model supports a richer valuation than where the shares trade today. Find out what Globus Medical could be worth using our Discounted Cash Flow (DCF) estimate.
The Globus Medical Narrative: What Would Justify Today's Price?
Narratives for Globus Medical pick up where the DCF puzzle leaves off by spelling out which paths for revenue growth, profitability and earnings would need to play out for the stock to end up meaningfully above or below today's market value on Simply Wall St's Community page. Each one treats Globus Medical's fair value as a thesis about how the business might evolve that you can revisit over time as new information arrives.
One of the top community narratives on Globus Medical: 30% undervalued
"Disciplined capital allocation, including use of roughly half of free cash flow for share repurchases, a debt free balance sheet with US$840.5 million of cash and securities…"
Discover why this Narrative puts Globus Medical at 30% undervalued.
For Globus Medical, who steers the ship matters as much as what it is worth
Price only tells part of the story for Globus Medical, because the people choosing how to spend cash and the way they are rewarded can quietly tilt long term outcomes in your favour or against it. See who runs Globus Medical and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com